By modulating the GH/IGF-1 axis, somatostatin analogs might counteract pro-survival and pro-proliferative signals in early mammary carcinogenesis, rendering them candidates for preventing breast cancer—particularly in individuals with elevated baseline IGF-1. This evidence concerns the gene IGF1 and breast carcinoma.